Company Filing History:
Years Active: 2019-2020
Title: Ségolène Laage: Innovator in Pharmaceutical Solutions
Introduction
Ségolène Laage is a distinguished inventor based in Lyons, France, known for his substantial contributions to pharmaceutical innovations. With a focus on injectable solutions, Laage has secured three patents that advance the field of diabetes management through improved insulin formulations.
Latest Patents
Laage's recent patents include an injectable solution at pH 7 comprising at least one basal insulin with an isoelectric point (pI) ranging from 5.8 to 8.5, along with a prandial insulin and/or a gastrointestinal hormone and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals. Another notable patent features physically stable compositions in an injectable aqueous solution, optimized for a pH of 6.0 to 8.0, incorporating similar components. His work also includes compositions with human glucagon combined with a statistical co-polyamino acid, aimed at providing stable and effective injectable solutions.
Career Highlights
Ségolène Laage is associated with Adocia, a company dedicated to the development of innovative medical treatments. His work has contributed significantly to advancing therapeutic options for diabetes, demonstrating his expertise in pharmaceutical formulations and injectable technologies.
Collaborations
Throughout his career, Laage has collaborated with talented professionals, including colleagues Alexandre Geissler and Olivier Soula. These partnerships foster the creation of effective pharmaceutical solutions, reflecting a commitment to medical research and innovation.
Conclusion
Ségolène Laage's innovative contributions and focus on injectable solutions position him as a key player in the pharmaceutical industry. His patents not only enhance the understanding of insulin management but also contribute to the overall improvement of patient care in diabetes treatment.